PapersFlow Research Brief
Inflammatory mediators and NSAID effects
Research Guide
What is Inflammatory mediators and NSAID effects?
Inflammatory mediators and NSAID effects refer to the biological mechanisms by which non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the production of prostaglandins and other eicosanoids derived from arachidonic acid, thereby reducing inflammation, pain, and associated pathological processes including cancer promotion.
This field encompasses 95,844 published works examining how NSAIDs like aspirin, rofecoxib, celecoxib, and naproxen target cyclooxygenase enzymes to block prostaglandin synthesis. Vane (1971) established that inhibition of prostaglandin synthesis underlies the anti-inflammatory action of aspirin-like drugs. Prostaglandins such as PGE2 sustain inflammation and contribute to cancer growth, while selective COX-2 inhibitors reduce gastrointestinal toxicity compared to nonselective NSAIDs.
Topic Hierarchy
Research Sub-Topics
COX-2 Inhibitors Gastrointestinal Toxicity
This sub-topic examines the mechanisms and incidence of gastrointestinal adverse effects, such as ulcers and bleeding, associated with COX-2 selective inhibitors like celecoxib and rofecoxib compared to non-selective NSAIDs. Researchers study clinical trial data, endoscopic findings, and risk mitigation strategies in patients with arthritis and other inflammatory conditions.
COX-2 Inhibitors Cardiovascular Risk
This sub-topic investigates the increased risk of myocardial infarction, stroke, and hypertension linked to COX-2 inhibitors, particularly rofecoxib. Researchers analyze epidemiological data, molecular pathways involving thromboxane and prostacyclin imbalance, and post-marketing surveillance outcomes.
Prostaglandin E2 in Cancer Progression
This sub-topic explores how PGE2, synthesized via COX-2, promotes tumor growth, angiogenesis, and metastasis in cancers like colorectal carcinoma. Researchers investigate PGE2 receptor signaling, autocrine/paracrine effects, and inhibition strategies using NSAIDs.
NSAIDs in Colorectal Cancer Chemoprevention
This sub-topic evaluates the efficacy of NSAIDs like aspirin and celecoxib in reducing colorectal adenoma and carcinoma incidence through COX-2 inhibition. Researchers conduct meta-analyses of randomized trials and study polyp regression mechanisms.
Prostaglandins in Immune Modulation
This sub-topic covers the regulatory effects of prostaglandins, especially PGE2, on T-cell differentiation, macrophage function, and cytokine production during inflammation. Researchers examine eicosanoid signaling in immune suppression and NSAID impacts on adaptive immunity.
Why It Matters
NSAIDs modulate inflammatory mediators to treat conditions like rheumatoid arthritis and osteoarthritis while posing risks of gastrointestinal and cardiovascular toxicity. Bombardier et al. (2000) in "Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis" found rofecoxib associated with significantly fewer upper gastrointestinal events than naproxen in rheumatoid arthritis patients. Silverstein et al. (2000) in "Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis" reported celecoxib at higher dosages linked to lower incidence of symptomatic ulcers and complications versus standard NSAIDs. These findings guide clinical use in balancing chemopreventive benefits against toxicity in inflammation and cancer contexts.
Reading Guide
Where to Start
"Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs" by Vane (1971), as it provides the foundational explanation of how NSAIDs block prostaglandin production central to all subsequent work on inflammatory mediators.
Key Papers Explained
Vane (1971) in "Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs" establishes NSAID mechanism by blocking cyclooxygenase. Funk (2001) in "Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology" expands on eicosanoid biology including prostaglandins in inflammation. Ricciotti and FitzGerald (2011) in "Prostaglandins and Inflammation" builds on these by detailing prostaglandin roles in pathogenesis. Bombardier et al. (2000) and Silverstein et al. (2000) apply these insights to clinical comparisons of rofecoxib versus naproxen and celecoxib versus NSAIDs, quantifying toxicity differences.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current focus remains on unresolved risks from COX-2 inhibitors like rofecoxib and celecoxib in inflammation-cancer contexts, with no recent preprints available. Emphasis persists on prostaglandin E2 modulation and cardiovascular implications from established trials.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | The obligatory role of endothelial cells in the relaxation of ... | 1980 | Nature | 12.0K | ✕ |
| 2 | Inhibition of Prostaglandin Synthesis as a Mechanism of Action... | 1971 | Nature New Biology | 8.6K | ✕ |
| 3 | Lanthanum Chloride Inhibits LPS Mediated Expressions of Pro-In... | 2017 | Cellular Physiology an... | 5.7K | ✓ |
| 4 | In silico analysis enabling informed design for genome editing... | 2019 | OPAL (Open@LaTrobe) (L... | 4.2K | ✓ |
| 5 | Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and... | 2000 | New England Journal of... | 4.0K | ✓ |
| 6 | Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology | 2001 | Science | 3.7K | ✕ |
| 7 | Aspirin in the primary and secondary prevention of vascular di... | 2009 | The Lancet | 3.6K | ✓ |
| 8 | Prostaglandins and Inflammation | 2011 | Arteriosclerosis Throm... | 3.6K | ✓ |
| 9 | An enzyme isolated from arteries transforms prostaglandin endo... | 1976 | Nature | 3.6K | ✕ |
| 10 | Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-... | 2000 | JAMA | 3.2K | ✕ |
Frequently Asked Questions
What is the primary mechanism of NSAID action on inflammatory mediators?
NSAIDs inhibit cyclooxygenase enzymes, blocking arachidonic acid conversion to prostaglandins. Vane (1971) in "Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs" demonstrated this as the core anti-inflammatory mechanism. Prostaglandins mediate pain, fever, and inflammation, so their suppression reduces these effects.
How do selective COX-2 inhibitors like rofecoxib compare to naproxen in gastrointestinal safety?
Rofecoxib shows fewer clinically important upper gastrointestinal events than naproxen. Bombardier et al. (2000) in "Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis" confirmed this in rheumatoid arthritis patients. The selective COX-2 inhibition spares gastrointestinal-protective prostaglandins produced by COX-1.
What role do prostaglandins play in inflammation?
Prostaglandins derived from arachidonic acid via cyclooxygenase sustain inflammatory responses. Ricciotti and FitzGerald (2011) in "Prostaglandins and Inflammation" explain they mediate pathogenic mechanisms including inflammation while also supporting homeostasis. NSAIDs block their biosynthesis to alleviate symptoms.
How does celecoxib affect gastrointestinal toxicity versus traditional NSAIDs?
Celecoxib reduces symptomatic ulcers and complications compared to standard NSAIDs. Silverstein et al. (2000) in "Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis" observed lower incidence at supratherapeutic doses. This stems from COX-2 selectivity minimizing COX-1 inhibition.
What is the involvement of prostaglandins in cancer?
Prostaglandins like PGE2 promote cancer growth and modulate immune responses. Funk (2001) in "Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology" notes their role in inflammation-linked oncogenesis. COX-2 inhibitors show chemopreventive potential by suppressing these mediators.
Open Research Questions
- ? How do COX-2 selective NSAIDs balance cardiovascular risks against gastrointestinal benefits in long-term use?
- ? What specific prostaglandins drive colorectal cancer progression and how effectively do inhibitors target them?
- ? Can molecular insights into prostaglandin modulation improve NSAID selectivity to minimize toxicity?
- ? What are the precise roles of endothelial cells in NSAID-modulated inflammatory responses?
- ? How do leukotrienes interact with prostaglandins in NSAID-inhibited pathways during chronic inflammation?
Recent Trends
The field holds steady at 95,844 works with no reported 5-year growth data.
Core insights from high-citation papers like Vane with 8580 citations and Bombardier et al. (2000) with 4019 citations continue to define NSAID effects on prostaglandins.
1971No new preprints or news in the last 12 months indicate stable research emphasis on COX-2 inhibitors' toxicity profiles.
Research Inflammatory mediators and NSAID effects with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Inflammatory mediators and NSAID effects with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers